FDA Approves Pfizer’s Paxlovid to Treat COVID-19

Pfizer's Paxlovid is displayed in Pembroke Pines, Fla., on July 7, 2022. Joe Raedle/Getty Images

The U.S. Food and Drug Administration (FDA) on May 25 fully approved Pfizer’s oral antiviral medication Paxlovid to treat mild to moderate COVID-19 in adults at risk of severe infections.

This clears the way for the drugmaker to sell it at market rates once the U.S. government supplies dwindle.